VIR

SEC source: 0001209191-21-046012 · doc4.xml · nonDerivative · entry 2

Pang Phillip · CIK 0001787370 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,772

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.60 to $40.57 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-046012 · doc4.xml · nonDerivative · entry 1

Pang Phillip · CIK 0001787370 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 114,277

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-045554 · doc4.xml · nonDerivative · entry 3

MORE ROBERT J · CIK 0001207792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,699

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.91 to $46.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001209191-21-045554 · doc4.xml · nonDerivative · entry 2

MORE ROBERT J · CIK 0001207792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,589

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.84 to $45.77, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001209191-21-045554 · doc4.xml · nonDerivative · entry 1

MORE ROBERT J · CIK 0001207792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,575

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.81 to $44.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001062993-21-006363 · form4.xml · nonDerivative · entry 3

NELSEN ROBERT · CIK 0001219042 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,825

F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration.

F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person.

SEC source: 0001062993-21-006363 · form4.xml · nonDerivative · entry 2

NELSEN ROBERT · CIK 0001219042 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 12,229,488

F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration.

F3 · ownership.nature: The shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). The Reporting Person is a managing director of ARCH Venture Partners IX, LLC, the sole general partner of ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), which is the sole general partner of ARCH Overage, and shares voting and investment control with respect to shares held by ARCH Overage. The Reporting Person disclaims ownership of such shares, except to the extent of his pecuniary interest therein.

SEC source: 0001062993-21-006363 · form4.xml · nonDerivative · entry 1

NELSEN ROBERT · CIK 0001219042 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 9,437,175

F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration.

F2 · ownership.nature: The shares are held by ARCH Venture Fund IX, L.P. ("ARCH IX"). The Reporting Person is a managing director of ARCH Venture Partners IX, LLC, the sole general partner of ARCH Venture Partners IX, L.P., which is the sole general partner of ARCH IX, and shares voting and investment control with respect to shares held by ARCH IX. The Reporting Person may be deemed to beneficially own the shares held by ARCH IX, and the Reporting Person disclaims ownership of such shares, except to the extent of his pecuniary interest therein.

SEC source: 0001062993-21-006362 · form4.xml · nonDerivative · entry 4

ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner

ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner

ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner

ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner

ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner

CRANDELL KEITH · CIK 0001219039 · 10% owner

BYBEE CLINTON · CIK 0001219043 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,229

F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration.

F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person.

F6 · ownership.direct: Shares held directly by Bybee.

SEC source: 0001062993-21-006362 · form4.xml · nonDerivative · entry 3

ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner

ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner

ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner

ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner

ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner

CRANDELL KEITH · CIK 0001219039 · 10% owner

BYBEE CLINTON · CIK 0001219043 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,241

F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration.

F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person.

F5 · ownership.direct: Shares held directly by Crandell.

SEC source: 0001062993-21-006362 · form4.xml · nonDerivative · entry 2

ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner

ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner

ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner

ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner

ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner

CRANDELL KEITH · CIK 0001219039 · 10% owner

BYBEE CLINTON · CIK 0001219043 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 12,229,488

F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration.

F3 · ownership.nature: These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by ARCH Overage. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by ARCH Overage. Each of Overage GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.

SEC source: 0001062993-21-006362 · form4.xml · nonDerivative · entry 1

ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner

ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner

ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner

ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner

ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner

CRANDELL KEITH · CIK 0001219039 · 10% owner

BYBEE CLINTON · CIK 0001219043 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 9,437,175

F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration.

F2 · ownership.nature: These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH IX. As managing directors of GPLLC, each of Keith Crandell and Clinton Bybee (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH IX. Each of GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.

SEC source: 0001209191-21-049147 · doc4.xml · nonDerivative · entry 1

MORE ROBERT J · CIK 0001207792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,700

F1 · kind: On July 1, 2021, the reporting person became entitled to receive 1,671 shares of the Issuer's common stock pursuant to an "earn-out" right in a letter agreement (the "Letter Agreement") entered into in connection with the Issuer's acquisition of all equity interests of TomegaVax, Inc. ("TomegaVax") on September 12, 2016 (the "TomegaVax Merger"). The Letter Agreement provides for certain payments to TomegaVax's former stockholders, for no additional consideration, prior to September 2024, in each case so long as the Issuer is continuing to pursue the development of the TomegaVax technology.

F2 · kind: Under the terms of the Letter Agreement, the Issuer will be required to pay to the former stockholders of TomegaVax milestone payments of up to an aggregate of $30.0 million if the per-share price of the Issuer's publicly traded common stock, or implied price per share of the Issuer's Series A-1 convertible preferred stock (or common stock upon conversion) upon a certain asset sale, merger or stock sale, is at least $45 (as adjusted in the case of any stock dividend, stock split or other similar recapitalization), with the amount of such payments determined by the share price and/or the stage of the Issuer's clinical development at the time of the relevant event triggering the payment. The share price of the Issuer's publicly traded common stock will be determined using the average of the daily volume-weighted average trading price of the Issuer's common stock for each trading day during a consecutive 90-day period.

F3 · kind: The foregoing payments are payable (i) during any date after the completion of an initial public offering by the Issuer or any successor or affiliate controlling the TomegaVax technology, provided that no payment will be due before the first anniversary of the initial public offering, (ii) upon the sale of all assets related to the TomegaVax technology or (iii) upon a merger or stock sale of the Issuer or any successor or affiliate controlling the TomegaVax technology, in each case subject to certain conditions with respect to the timing of the payments. The payments under the Letter Agreement can be made in cash or shares of the Issuer's common stock, at the discretion of the Issuer's board of directors. On February 24, 2021, the Issuer achieved one of the milestones related to the specified per-share price of its common stock, which resulted in a $10.0 million payable to TomegaVax's former stockholders within 90 business days of achieving such milestone.

F4 · kind: The number of shares issuable pursuant to the earn-out right was determined on July 1, 2021 (90 business days after the achievement of such milestone) based on the closing price of the Issuer's common stock on such date, as provided in the Letter Agreement. On July 9, 2021, the Issuer completed the milestone payment to the former TomegaVax stockholders, including the reporting person, through a combination of cash payment and shares of common stock as determined by the Issuer's board of directors. The reporting person's right to receive additional shares became fixed and irrevocable on September 12, 2016, the effective date of the TomegaVax Merger.

F5 · kind: The remaining $20.0 million in milestone payments will be triggered if (i) the per-share price of the Issuer's publicly traded common stock is at least $45 (as adjusted in the case of any stock dividend, stock split or other similar recapitalization) and upon the achievement of a certain milestone related to the stage of the Issuer's clinical development at the time of the relevant event triggering the payment or (ii) the per-share price of the Issuer's publicly traded common stock is at least $90 (as adjusted in the case of any stock dividend, stock split or other similar recapitalization). The foregoing description of the terms of the Letter Agreement is qualified in its entirety by reference to the full text of the Letter Agreement, a copy of which was filed as Exhibit 10.31 to the Issuer's Annual Report on Form 10-K for the year-ended December 31, 2020 filed with the Securities and Exchange Commission on February 25, 2021.

SEC source: 0001209191-21-044166 · doc4.xml · derivative · entry 3

Virgin Herbert · CIK 0001786378 · EVP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 289,380

Underlying: Common Stock · 1,375 shares

Expires 2028-01-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-21-044166 · doc4.xml · nonDerivative · entry 2

Virgin Herbert · CIK 0001786378 · EVP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,700

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020.

SEC source: 0001209191-21-044166 · doc4.xml · nonDerivative · entry 1

Virgin Herbert · CIK 0001786378 · EVP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,075

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-043698 · doc4.xml · derivative · entry 3

Rice Steven J. · CIK 0001820108 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 444,441

Underlying: Common Stock · 3 shares

Expires 2029-12-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vest and become exercisable on September 15, 2020, and the remainder vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-21-043698 · doc4.xml · nonDerivative · entry 2

Rice Steven J. · CIK 0001820108 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021.

SEC source: 0001209191-21-043698 · doc4.xml · nonDerivative · entry 1

Rice Steven J. · CIK 0001820108 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,003

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-043032 · doc4.xml · derivative · entry 2

Virgin Herbert · CIK 0001786378 · EVP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 290,755

Underlying: Common Stock · 8,000 shares

Expires 2028-01-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-21-043032 · doc4.xml · nonDerivative · entry 1

Virgin Herbert · CIK 0001786378 · EVP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,700

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001062993-21-005943 · form4.xml · nonDerivative · entry 3

NELSEN ROBERT · CIK 0001219042 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,928

F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration.

F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person.

SEC source: 0001062993-21-005943 · form4.xml · nonDerivative · entry 2

NELSEN ROBERT · CIK 0001219042 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 14,487,240

F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration.

F3 · ownership.nature: The shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). The Reporting Person is a managing director of ARCH Venture Partners IX, LLC, the sole general partner of ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), which is the sole general partner of ARCH Overage, and shares voting and investment control with respect to shares held by ARCH Overage. The Reporting Person disclaims ownership of such shares, except to the extent of his pecuniary interest therein.

SEC source: 0001062993-21-005943 · form4.xml · nonDerivative · entry 1

NELSEN ROBERT · CIK 0001219042 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 11,179,423

F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration.

F2 · ownership.nature: The shares are held by ARCH Venture Fund IX, L.P. ("ARCH IX"). The Reporting Person is a managing director of ARCH Venture Partners IX, LLC, the sole general partner of ARCH Venture Partners IX, L.P., which is the sole general partner of ARCH IX, and shares voting and investment control with respect to shares held by ARCH IX. The Reporting Person may be deemed to beneficially own the shares held by ARCH IX, and the Reporting Person disclaims ownership of such shares, except to the extent of his pecuniary interest therein.

SEC source: 0001062993-21-005942 · form4.xml · nonDerivative · entry 4

ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner

ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner

ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner

ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner

ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner

CRANDELL KEITH · CIK 0001219039 · 10% owner

BYBEE CLINTON · CIK 0001219043 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,096

F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration.

F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person.

F6 · ownership.direct: Shares held directly by Bybee.

SEC source: 0001062993-21-005942 · form4.xml · nonDerivative · entry 3

ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner

ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner

ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner

ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner

ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner

CRANDELL KEITH · CIK 0001219039 · 10% owner

BYBEE CLINTON · CIK 0001219043 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,962

F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration.

F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person.

F5 · ownership.direct: Shares held directly by Crandell.

SEC source: 0001062993-21-005942 · form4.xml · nonDerivative · entry 2

ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner

ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner

ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner

ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner

ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner

CRANDELL KEITH · CIK 0001219039 · 10% owner

BYBEE CLINTON · CIK 0001219043 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 14,487,240

F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration.

F3 · ownership.nature: These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by ARCH Overage. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by ARCH Overage. Each of Overage GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.

SEC source: 0001062993-21-005942 · form4.xml · nonDerivative · entry 1

ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner

ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner

ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner

ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner

ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner

CRANDELL KEITH · CIK 0001219039 · 10% owner

BYBEE CLINTON · CIK 0001219043 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 11,179,423

F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration.

F2 · ownership.nature: These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH IX. As managing directors of GPLLC, each of Keith Crandell and Clinton Bybee (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH IX. Each of GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.

SEC source: 0001209191-21-042578 · doc4.xml · nonDerivative · entry 2

SATO VICKI L · CIK 0001197020 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,642,136

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.545 to $47.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001209191-21-042578 · doc4.xml · nonDerivative · entry 1

SATO VICKI L · CIK 0001197020 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,645,429

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.43 to $46.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001209191-21-042116 · doc4.xml · nonDerivative · entry 1

MORE ROBERT J · CIK 0001207792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,369

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.64 to $44.31, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001209191-21-041516 · doc4.xml · derivative · entry 3

Pang Phillip · CIK 0001787370 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,129

Underlying: Common Stock · 5,000 shares

Expires 2029-03-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on March 11, 2020, and the remaining shares will vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-21-041516 · doc4.xml · nonDerivative · entry 2

Pang Phillip · CIK 0001787370 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,277

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.19 to $43.95 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-041516 · doc4.xml · nonDerivative · entry 1

Pang Phillip · CIK 0001787370 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 114,277

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-041514 · doc4.xml · derivative · entry 3

Virgin Herbert · CIK 0001786378 · EVP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 298,755

Underlying: Common Stock · 1,375 shares

Expires 2028-01-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-21-041514 · doc4.xml · nonDerivative · entry 2

Virgin Herbert · CIK 0001786378 · EVP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,700

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020.

SEC source: 0001209191-21-041514 · doc4.xml · nonDerivative · entry 1

Virgin Herbert · CIK 0001786378 · EVP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 93,075

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-038772 · doc4.xml · nonDerivative · entry 1

MORE ROBERT J · CIK 0001207792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,039

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.02 to $45.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001209191-21-037937 · doc4.xml · derivative · entry 4

Pang Phillip · CIK 0001787370 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,833

Underlying: Common Stock · 10,000 shares

Expires 2027-03-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: 1/4 of the 111,110 shares originally subject to the stock option vested and became exercisable on December 14, 2017, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-21-037937 · doc4.xml · nonDerivative · entry 3

Pang Phillip · CIK 0001787370 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,277

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.09 to $42.23 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-037937 · doc4.xml · nonDerivative · entry 2

Pang Phillip · CIK 0001787370 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,577

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.08 to $42.06 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-037937 · doc4.xml · nonDerivative · entry 1

Pang Phillip · CIK 0001787370 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 119,277

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-037342 · doc4.xml · derivative · entry 3

Virgin Herbert · CIK 0001786378 · EVP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 300,130

Underlying: Common Stock · 1,375 shares

Expires 2028-01-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-21-037342 · doc4.xml · nonDerivative · entry 2

Virgin Herbert · CIK 0001786378 · EVP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,700

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020.

SEC source: 0001209191-21-037342 · doc4.xml · nonDerivative · entry 1

Virgin Herbert · CIK 0001786378 · EVP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 93,075

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-035717 · doc4.xml · derivative · entry 2

Sigal Charles Elliott · CIK 0001661908 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,748

Underlying: Common Stock · 6,748 shares

Expires 2031-05-20

SEC source: 0001209191-21-035717 · doc4.xml · nonDerivative · entry 1

Sigal Charles Elliott · CIK 0001661908 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,374

SEC source: 0001209191-21-035716 · doc4.xml · derivative · entry 5

SHARP PHILLIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,748

Underlying: Common Stock · 6,748 shares

Expires 2031-05-20

SEC source: 0001209191-21-035716 · doc4.xml · nonDerivative · entry 1

SHARP PHILLIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 108,742

SEC source: 0001209191-21-035715 · doc4.xml · derivative · entry 2

Ramasastry Saira · CIK 0001547959 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,748

Underlying: Common Stock · 6,748 shares

Expires 2031-05-20